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Abstract: Objective: Biguanides are anti-diabetic drugs that are thought to have anti-tumorigenic effects. Most pre-
clinical studies have focused on metformin for cancer treatment and prevention; however, buformin may be po-
tentially more potent than metformin. Given this, our goal was to evaluate the effects of buformin on cell growth, 
adhesion and invasion in endometrial cancer cell lines. Methods: The ECC-1 and Ishikawa endometrial cancer cell 
lines were used. Cell proliferation was assessed by MTT assay. Apoptosis and cell cycle analysis was performed by 
FITC Annexin V assay and propidium iodide staining, respectively. Adhesion was analyzed using the laminin adhe-
sion assay. Invasion was assessed using the transwell invasion assay. The effects of buformin on the AMPK/mTOR 
pathway were determined by Western immunoblotting. Results: Buformin and metformin inhibited cell proliferation 
in a dose-dependent manner in both endometrial cancer cell lines. IC50s were 1.4-1.6 mM for metformin and 8-150 
μM for buformin. Buformin induced cell cycle G1 phase arrest in the ECC-1 cells and G2 phase arrest in the Ishikawa 
cells. For both ECC-1 and Ishikawa cells, treatment with buformin resulted in induction of apoptosis, reduction in 
adhesion and invasion, activation of AMPK and inhibition of phosphorylated-S6. Buformin potentiated the anti-
proliferative effects of paclitaxel in both cell lines. Conclusion: Buformin has significant anti-proliferative and anti-
metastatic effects in endometrial cancer cells through modulation of the AMPK/mTOR pathway. IC50 values were 
lower for buformin than metformin, suggesting that buformin may be more potent for endometrial cancer treatment 
and worthy of further investigation.
Keywords: Endometrial cancer, buformin, proliferation, invasion
Introduction
Endometrial cancer is the fourth most common 
cancer among women with an estimated 
54,870 new cases diagnosed and 10,170 
deaths in the United States in 2015 [1]. The 
incidence of this disease has increased over 
the past few decades, largely due to the grow-
ing obesity epidemic, with women now having a 
1 in 38 lifetime risk of developing endometrial 
cancer. Obesity, diabetes and insulin resis-
tance are well-known factors associated with 
both increased risk of developing endometrial 
cancer [2, 3] and increased risk of death [4-6]. 
Despite available chemotherapy, overall 5-year 
survival for advanced endometrial cancer 
remains poor at 21-56%. Thus, there is a great 
need for novel agents to improve endometrial 
cancer outcomes.
A growing body of evidence suggests that the 
class of drugs known as biguanides may be 
effective as anti-cancer agents [7]. Three bigu-
anides, metformin, phenformin and buformin, 
have been used in the treatment of non-insulin-
dependent diabetes mellitus. Metformin has 
been marketed in the United States since 1995 
[8]. Buformin and phenformin are not approved 
for use in the United States due to increased 
risk of lactic acidosis. In recent years, epidemio-
logic evidence has shown that diabetic patients 
treated with biguanide drugs have a reduced 
risk of developing cancer compared with 
patients receiving sulfonylureas [7, 9]. In vitro 
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studies of metformin and phenformin in a 
variety of cancers have demonstrated that 
these drugs cause disruption of mitochondrial 
respiration leading to activation of AMP-ac- 
tivated protein kinase (AMPK) and inhibition of 
the mammalian target of rapamycin (mTOR) 
pathway, ultimately resulting in the inhibition of 
cellular proliferation, induction of apoptosis, 
cell cycle arrest and a reduction in protein and 
lipid synthesis [10-13]. In vivo studies have indi-
cated that metformin and phenformin have 
promising anti-tumorigenic activity in breast 
cancer, colon cancer and ovarian cancer mouse 
models, among others [11-14]. Currently, met-
formin is being investigated in greater than 50 
phase I, II and III clinical trials in multiple types 
of cancer, including endometrial cancer [15]. 
Looking beyond metformin at other biguanide 
drugs, the role for phenformin and buformin as 
potential anti-cancer agents has recently been 
investigated. Phenformin and buformin are 
appealing drugs compared to metformin, as 
they are more lipophilic and more potent inhibi-
tors of mitochondrial complex I and cellular ATP 
production [16-18]. The major limitation of 
buformin and phenformin is their increased risk 
of lactic acidosis. Phenformin is associated 
with a 10- to 20-fold increased risk of lactic aci-
dosis compared to metformin, and there is lim-
ited data about the incidence of buformin-asso-
ciated lactic acidosis [19]. Renal secretion is 
required for clearance of biguanides, and near-
ly all episodes of lactic acidosis associated with 
biguanides have occurred in patients with renal 
dysfunction [20]. Careful patient selection and 
observation may allow this side effect to be 
minimized. Moreover, treating cells with a com-
bination of phenformin and 2-deoxyglucose or 
a lactate dehydrogenase (LDH) inhibitor, can 
avoid development of lactic acidosis [13].  
Given that (1) biguanides have demonstrated 
beneficial chemopreventive and chemothera-
peautic effects in a number of cancers and (2) 
buformin may be more potent than metformin 
in inhibition of energy metabolism in cancer 
cells [10, 15, 21-23], buformin warrants further 
evaluation as a potential drug for cancer thera-
py. Thus, the aim of this study was to investi-
gate the anti-tumorigenic and anti-metastatic 
effects of buformin in endometrial cancer cell 
lines. 
Materials and methods
Cell culture and reagents
Two endometrial cancer cell lines, ECC-1 and 
Ishikawa, were used for all experiments. The 
ECC-1 cells were grown in RPMI 1640 medium 
supplemented with 5% bovine, 100 units/ml 
penicillin and 100 ug/ml streptomycin under 
5% CO2. The Ishikawa cells were grown in MEM 
supplemented with 5% fetal bovine serum, 300 
mM l-glutamine, 10,000 U/ml penicillin and 
10,000 μg/ml streptomycin under 5% CO2. 
Metformin, paclitaxel, RNase, and RIPA buffer 
was purchased from Sigma (St. Louis, MO). 
Buformin was purchased from Santa Cruz 
(Dallas, Texas). Metformin and Buformin were 
re-suspended in PBS. Paclitaxel was soluble in 
DMSO. Antibodies to phosphorylated-AMPK 
(Thr172), phosphorylated-S6 (Ser235/236), 
β-actin, pan-AMPK and pan-S6 were obtained 
from Cell Signaling Technology (Beverly, MA). 
The Annexin V FITC kit was purchased from 
BioVision (Mountain View, CA). Enhanced che-
miluminescence western immunoblotting de-
tection reagents were purchased from Amer- 
sham (Arlington Heights, IL). All other chemi-
cals were purchased from Sigma. 
Cell proliferation assay
The ECC-1 and Ishikawa cells were plated and 
grown in 96-well plates at a concentration of 
5000 cells/well for 24 hours. These cells were 
then treated with various concentrations of 
buformin and metformin for a period of 72 
hours. After the addition of MTT dye (5 mg/mL), 
the 96-well plates were incubated for 1-2 hours 
at 37°C. 100 uL of DMSO was added to the 
plates in order to terminate the MTT reaction, 
and the plates were read by measuring 
absorption at 595 nm. The effect of buformin 
and metformin was calculated as a percen- 
tage of control cell growth obtained from PBS 
(1%) treated cells grown in the same 96-well 
plates. Each experiment was repeated three 
times to assess for consistency of results. 
Cell cycle analysis 
The effect of buformin on cell cycle progression 
was assessed using Cellometer (Nexcelom, 
Lawrence, MA). In short, cells were plated at a 
density of 2 × 105 cells/well in 6-well plates 
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overnight and then treated with varying concen-
trations of buformin for 48 hours. Cells were 
collected by 0.05% trypsin (Gibco Grand Island, 
NY), washed with phosphate-buffered saline 
(PBS) solution, fixed in a 90% methanol solu-
tion and then stored at -20°C until cell cycle 
analysis was performed. On the day of analysis, 
the cells were washed with PBS and centri-
fuged, resuspended in 50 ul RNase A solution 
(250 ug/ml) with 10 mM EDTA, followed by 
incubation for 30 min at 37°C. After incubation, 
50 µl of propidium iodide (PI) staining solution 
(2 mg/ml PI, 0.1 mg/ml Azide and 0.05% Triton 
X-100) was added to each tube and incubated 
for 10 min in the dark. The cells were assessed 
by Cellometer. The results were analyzed using 
FCS4 express software (Molecular Devices, 
Sunnyvale, CA). Each experiment was repeated 
at least twice for consistency of response.
Annexin V assay
The effect of buformin on cell apoptosis was 
detected using the Annexin-V FITC kit. Briefly, 2 
× 105 cells/well were seeded into 6-well plates 
overnight and then the cells were cultured in 
media with varying concentrations of buformin 
for 24 hours. The cells were collected by 0.25% 
trypsin without EDTA. After PBS washing, cells 
were resuspended in 100 ul of Annexin-V and 
PI dual-stain solution (0.1 ug of Annexin-V FITC 
and 1 ug of PI) for 15 min in the dark. Apoptotic 
cells were detected by Cellometer. The results 
were analyzed by FCS4 express software. Each 
experiment was repeated at least twice for con-
sistency of response.
Adhesion assay 
Each well in a 96-well plate was coated with 
100 ul laminin-1 (10 ug/ml) and incubated at 
37°C for 1 hour. This fluid was then aspirated, 
and 200ul blocking buffer was added to each 
well for 45-60 min at 37°C. The wells were then 
washed with PBS, and the plate was allowed to 
chill on ice. To each well, 2.5 × 103 cells were 
added with PBS and varying concentrations of 
buformin directly. The plate was then allowed to 
incubate at 37°C for 2 hours. After this period, 
the medium was aspirated, and cells were fixed 
by directly adding 100 ul of 5% glutaraldehyde 
and incubating for 30 min at room tempera-
ture. Adhered cells were then washed with PBS 
and stained with 100 ul of 0.1% crystal violet 
for 30 minutes. The cells were then washed 
repeatedly with water, and 100 ul of 10% acetic 
acid was added to each well to solubilize the 
dye. After 5 minutes of shaking, the absor-
bance was measured at 570 nm using a micro-
plate reader from Tecan (Morrisville, NC). Each 
experiment was repeated at least twice for con-
sistency of response.
Invasion assay
Cell invasion assays were performed using 
96-well HTS transwells (Corning Life Sciences, 
Durham, NC) coated with 0.5-1X BME (Trevigen, 
Gaithersburg, MD). The ECC-1 and Ishikawa 
cells (50,000/well) were starved for 12 hours 
and then seeded in the upper chambers of the 
wells in 50 μl FBS-free medium. The lower 
chambers were filled with 150 μl regular medi-
um with buformin. The plate was incubated for 
24 hours at 37°C to allow invasion into the 
lower chamber. After washing the upper and 
lower chambers with PBS, 100 ul Calcein AM 
solution was added into the lower chamber and 
incubated at 37°C for 30-60 min. The lower 
chamber plate was measured by the plate read-
er for reading fluorescence at EX/EM 485/520 
nM. Each experiment was repeated at least 
twice for consistency of response.
Western immunoblotting
The ECC-1 and Ishikawa cells were plated at 2 
× 105 cells/well in 6 well plates in their appro-
priate medium and were treated for 24 hours 
with buformin. Cell lysates were prepared in 
RIPA buffer (1% NP40, 0.5 sodium deoxycholate 
and 0.1% SDS) plus PhosStop. Equal amounts 
of protein were separated by gel electrophore-
sis and transferred onto a PVDF membrane. 
The membrane was blocked with 5% nonfat dry 
milk and then incubated with a 1:1000 dilution 
of primary antibody overnight at 4°C. The mem-
brane was then washed and incubated with a 
secondary peroxidase conjugated antibody for 
1 hour after washing. Antibody binding was 
detected using an enhanced chemilumines-
cence detection buffer by Alpha Innotech imag-
ing system (San Leandro, CA). Each experiment 
was repeated three times to assess for consis-
tency of results. 
Statistical analysis
Data were presented as mean ± standard error 
of the mean. Comparisons between groups 
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were determined with the two-sided unpaired 
student’s t-test using GraphPad software (La 
Jolla, CA USA). A value of p<0.05 was consid-
ered as significant.
Figure 1. Effect of buformin and metformin on cell proliferation in endometrial cancer cells. The ECC-1 (A) and 
Ishikawa (B) cell lines were cultured in the presence of varying concentrations of buformin and metformin for 72 h. 
Cell proliferation was determined by MTT assay. The results are shown as the mean ± SE of triplicate samples and 
are representative of three independent experiments.  
Figure 2. Effect buformin on cell cycle and apoptosis in the Ishikawa and ECC-1 cell lines. The cells were treated with 
buformin at different doses for 48 h and cell cycle was analyzed by Cellometer. Buformin induced cell cycle arrest in 
G1 phase in the ECC-1 (A) cells and in G2 phase in the Ishikawa (B) cells. The ECC-1 and Ishikawa cells were grown 
for 24 h and then treated with buformin at the indicated concentrations for an additional 24 h. Annexin V expression 
was detected by Cellometer. Buformin induced apoptosis in the Ishikawa cells (D), but not in the ECC-1 cells (C). The 
results are shown as the mean ± SD and are representative of three independent experiments. **p<0.01.
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Results
Comparison of buformin with metformin in the 
inhibition of cell proliferation in endometrial 
cancer cells
The effects of buformin and metformin on cell 
proliferation were examined in the endometrial 
cancer cell lines, ECC-1 and Ishikawa. Both cell 
lines were exposed to varying doses of bufor-
min and metformin for 72 hours. Both buformin 
and metformin inhibited cell growth in a dose-
dependent manner in both endometrial cancer 
cell lines. The mean IC50 value for metformin 
was 1.6 mM in the ECC-1 cells and 1.4 mM in 
the Ishikawa cells, after 72 hours of treatment. 
For the cells treated with buformin, the mean 
IC50 value was approximately 150 μM and 8 
μM for the ECC-1 and Ishikawa cells at 72 
hours, respectively (Figure 1A and 1B). These 
results suggest that both metformin and bufor-
min effectively inhibit cell proliferation in endo-
metrial cancer cells; however, buformin app- 
eared more potent than metformin, given the 
lower IC50 values for buformin over met- 
formin. 
Buformin induced cell cycle arrest 
To evaluate the underlying mechanism of 
growth inhibition by buformin, the cell cycle pro-
file was analyzed after treating the ECC-1 and 
Ishikawa cells with varying doses (1-1000 μM) 
of buformin for 48 hours. As illustrated in 
Figure 2A and 2B, buformin treatment resulted 
in G1 cell cycle arrest in the ECC-1 cells and 
increased G2 phase in the Ishikawa cells in a 
dose-dependent manner, suggesting that 
Figure 3. Effect of buformin on AMPK/mTOR/S6 pathway in ECC-1 and Ishikawa cells. The ECC-1 and Ishikawa (A) 
cell lines were treated with buformin (10 μM) in a time course fashion as indicated. Phosphorylated-AMPK, pan-
AMPK, phosphorylated-S6 and pan S-6 were detected by Western immunoblotting. Buformin increased phosphory-
lation of AMPK and decreased phosphorylation of S6 expression as determined in time course study. The ECC-1 
and Ishikawa (B) cells were treated with buformin at different concentrations for 24 h. Western blot results showed 
that buformin reduced phosphorylation of S6 expression in a dose dependent manner. The results are shown one 
of three independent experiments.
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buformin induced cell cycle arrest through dif-
ferent checkpoints among these two cell lines. 
Buformin induced apoptosis 
We assessed the effects of buformin on cell 
apoptosis using the Annexin V assay. This assay 
detects apoptotic cells by monitoring fluores-
cently labeled Annexin V, which binds to the 
phosphaticylserine (PS) externalized on the 
surface of cell membrane that is a distinct phe-
nomenon of early apoptosis [24]. The ECC-1 
and Ishikawa cells were treated with buformin 
at varying concentrations (1-1000 μM) over-
night. The percentage of apoptotic cells in- 
creased in a dose-dependent manner in the 
Ishikawa cells (Figure 2D). Buformin had no 
effect on the expression of Annexin V in the 
ECC-1 cells (Figure 2C). When combined with 
the cell cycle results, these data indicate that 
inhibition of cell proliferation by buformin may 
involve divergent pathways in different endo-
metrial cancer cells lines. 
Effect of buformin on the AMPK/mTOR path-
way
It is well known that activation of AMPK and 
inhibition of the mTOR pathway play a crucial 
role in control of cell growth survival in endome-
trial cancer, and targeting of these pathways 
leads to the inhibition of endometrial cancer 
growth [10, 15]. To investigate the mechanisms 
underlying the inhibition of cell growth by bufor-
min, we characterized the effect of buformin on 
these signaling pathways in a time course fash-
ion. Buformin increased phosphorylation of 
AMPK and decreased phosphorylation of S6 
expression in both endometrial cancer cell 
lines (Figure 3A). The greatest effects were 
seen in the ECC-1 cell line after 48 hours of 
exposure to buformin for both increased activa-
tion of AMPK and decreased phosphorylation 
of S6. For the Ishikawa cell line, maximal effects 
were seen after 12 hours of exposure to bufor-
min. Following this, we treated cells with bufor-
min at varying concentrations for 24 hours and 
evaluated the effect of different concentrations 
of buformin on the mTOR pathway. Buformin 
decreased phosphorylation of ribosomal pro-
tein S6 in a dose-dependent manner in both 
cancer cell lines (Figure 3B). These data sug-
gest that buformin exerts its anti-tumorigenic 
activity via activation of AMPK and inhibition of 
the mTOR signaling pathways in endometrial 
cancer cells. 
Buformin inhibits cell adhesion and invasion 
Adhesion and invasion are important steps 
leading to metastasis in endometrial cancer. In 
order to determine the effect of buformin on 
adhesion and invasion of endometrial cancer 
cells, an in vitro laminin adhesion assay and 
transwell invasion system were employed, 
respectively. Incubation of the ECC-1 and 
Ishikawa cell lines with buformin (10 and 100 
μM) for 2 hours showed significant inhibition of 
cell adhesion (22-31% in ECC-1 cells and 4-21% 
in Ishikawa cells, p<0.05) (Figure 4A). Buformin 
(10 and 100 uM) significantly blocked cell inva-
sion after 24 hours of treatment in both cell 
lines (15-28% in ECC-1 cells and 17-25% in 
Ishikawa cells, p<0.05) (Figure 4B). Inhibition 
Figure 4. Buformin inhibited adhesion and invasion in the ECC-1 and Ishikawa cells. To assess adhesion, the ECC-1 
and Ishikawa cell lines were treated with varying concentrations of buformin and plated in laminin-coated 96-well 
plates for 2 h (A). Invasion was assessed using transswell assay after 24 h of treatment with buformin (B). Buformin 
inhibited adhesion and invasion in both cell lines. The results are shown as the mean ± SD and are representative 
of three independent experiments. *p<0.05, **p<0.01. 
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of cell adhesion and invasion was dose-depen-
dent in both the ECC-1 and Ishikawa cell lines. 
Synergistic anti-proliferative effects of bufor-
min and paclitaxel
We have previously confirmed that metformin 
increased the sensitivity of endometrial cancer 
cells to paclitaxel [25]. We sought to determine 
if buformin had similar effects when combined 
with paclitaxel. We evaluated the effects of 
buformin and paclitaxel on cell proliferation in 
the ECC-1 and Ishikawa cells. Both cell lines 
were treated with serial dilutions of paclitaxel in 
combination with 0.1 or 1 μM of buformin for 
48 hours. Their individual and combined effects 
on growth inhibition were evaluated using 
Chou-Talalay method [25]. The addition of bu- 
formin at 0.1 or 1 uM to paclitaxel led to a 
greater inhibition of cell proliferation than that 
of paclitaxel alone (Figure 5A-D). The analysis 
of synergy quantification showed that the com-
bination buformin with paclitaxel resulted in 
significant synergistic anti-proliferative effects 
(95% CI of 0.104-0.561 for both cell lines).
Discussion
Based on pre-clinical and epidemiological data, 
biguanides are thought to have potentially ben-
eficial chemo-preventative and chemothera-
peutic effects. Buformin has broader tissue 
availability and greater potency compared to 
metformin but few studies have explored its 
anti-tumorigenic activity [7]. Early animal stud-
ies showed that long term use of buformin sig-
nificantly decreased the total spontaneous 
tumor incidence in rats by 49.5% [16]. Postnatal 
Figure 5. Buformin increased sensitivity to paclitaxel in the ECC-1 and Ishikawa cell lines. The ECC-1 (A and C) and 
Ishikawa (B and D) cell lines were cultured in the presence of varying concentrations of paclitaxel (0.1-10 nM) and 
buformin (0.1 or 1 μM) in regular medium for 48 h. Inhibition of cell growth was determined by MTT assay. The 
synergy between buformin and paclitaxel was calculated using Chou-Talalay equation at a dose of 0.1 and 1 μM of 
buformin in both cell lines (CI<1). The results are shown as the mean ± SE of triplicate samples and are representa-
tive of 3 independent experiments.  Bu=buformin, Tax=paclitaxel.
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treatment with buformin beginning at 2 months 
of age significantly reduced the incidence of 
malignant neurogenic tumors in rats exposed 
to N-nitrosomethylurea (NMU) transplacentally 
[18]. A recent study showed that buformin had 
greater inhibition of colony formation in human 
colon cancer HT-29 cells than metformin in 
both normal and glucose-free medium [26]. 
Additionally, buformin significantly decreased 
the incidence of adenocarcinoma of the mam-
mary gland in female rats induced by 7,12-dh- 
nethylbenz(a)anthracene (DMBA) and increased 
the mean latent period of detection of all neo-
plasms [27], indicating the efficacy of buformin 
in vivo. Lastly, buformin, but not phenformin or 
metformin, decreased cancer incidence, multi-
plicity and burden in the 1-methyl-1-nitro-
sourea-induced mammary carcinogenesis rat 
model, suggesting that inherent differences in 
biological action may exist among biguanides 
[28]. 
Our results find that buformin strongly inhibited 
the proliferation of both ECC-1 and Ishikawa 
cells in a dose-dependent manner. Buformin 
also showed greater potential in the inhibition 
of ECC-1 and Ishikawa cell growth than metfor-
min, as evidenced by lower IC50 values for 
buformin over metformin. Growth inhibition 
was accompanied by decreased cell adhesion 
and invasion, induction of cell cycle arrest, acti-
vation of AMPK and inhibition of the mTOR 
pathway. Moreover, buformin significantly 
increased the sensitivity of paclitaxel in the 
inhibition of cell proliferation in both cell lines. 
The results are in agreement with our previous 
studies examining the anti-tumorigenic activity 
of metformin in endometrial cancer cells [10, 
25], suggesting that buformin may be an effec-
tive agent in the treatment of endometrial 
cancer.
Several possible mechanisms related to the 
anti-tumorigenic activity of biguanides could be 
explained by the functional activation of AMPK 
[10, 11]. AMPK has pleiotropic effects on cellu-
lar metabolism and growth in most cancer 
cells. The mTOR signaling pathway is a key regu-
latory step in cellular growth in response to 
nutrients and growth factor changes. Through 
AMPK-dependent or -independent mechani- 
sms, metformin and phenformin have been 
shown to inhibit mTOR signaling and induce 
anti-tumorigenic effects [9, 15]. Buformin and 
metformin exhibit similar effects in the inhibi-
tion of phosphorylation of 4E-BP1 (a down-
stream target of mTOR) in fibrosarcoma HT10- 
80 cells, and immunohistochemical analysis 
showed a reduction in the expression of phos-
phorylated-4E-BP1 in xenografts of gastric can-
cer after intra-tumoral injection of buformin 
[29]. In this study, AMPK activation and inhibi-
tion of phosphorylated S6 expression were 
observed by Western immunoblotting in a 
dose-dependent and time-dependent manner 
in endometrial cancer cell lines after treatment 
with buformin. This is consistent with the pro-
posed mechanism of action of metformin and 
phenformin involving AMPK activation leading 
to mTOR inhibition. To our knowledge, this is the 
first study to evaluate the role of buformin on 
AMPK/mTOR signaling in endometrial cancer 
cells. 
The most common route of metastasis in endo-
metrial cancer is the direct extension of a tumor 
to the myometrium [30]. Cell adhesion and 
invasion are early steps in metastasis that 
involve tumor cell interaction, extracellular 
matrix (ECM) degradation and cell migration 
[31]. Clinically it is necessary to identify specific 
agents that may target the process of cell adhe-
sion and invasion, in addition to proliferation. 
Only a few studies have focused on the role of 
biguanides in the process of adhesion and 
invasion in cancer. It has been shown that met-
formin inhibits melanoma invasion by regulat-
ing the EMT-like regulatory factors through 
AMPK/p53 pathway [32]. Additionally, Tan et al 
found that in vitro invasion of endometrial can-
cer cells was significantly attenuated by sera 
from women with polycystic ovary syndrome 
(PCOS) after 6 months of metformin treatment 
(850 mg twice daily) compared to matched con-
trols. These effects appeared to be mediated 
through important regulators of inflammation 
including NF-kB, MMP-2 and MMP-9, as well as 
activation of Akt and Erk1/2 signaling path-
ways [33]. Our study is the first to demonstrate 
that buformin inhibits cell adhesion and inva-
sion of endometrial cancer. 
A concern surrounding the clinical use of bigu-
anides is the risk of lactic acidosis as a poten-
tial side effect. Biguanides impair mitochondri-
al respiration via inhibition of complex I, which 
can result in a compensatory acceleration of 
glycolysis to counteract the reduced ATP pro-
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duction via oxidative phosphorylation and a 
resultant increase in the production of lactic 
acid. Each biguanide is associated with varying 
risk of lactic acidosis with buformin and phen-
formin having an increased risk compared to 
metformin. In vivo data shows the IC50 values 
for development of lactic acidosis in rats to be 
5 μM for phenformin, 199 μM for buformin and 
735 μM for metformin [19]. Biguanides reduce 
oxygen consumption in isolated rat hepato-
cytes in a concentration-dependent manner, 
and the EC50 (the concentration of a drug that 
gives half-maximal response) values of bigua-
nides determined in vivo correlate with the 
increase of blood lactate, suggesting that oxy-
gen consumption may be used as an index for 
the incidence of lactic acidosis [21]. While the 
liver is largely responsible for lactic acid pro-
duction, the kidneys are critical to the clear-
ance of lactic acid. Patients with diabetes may 
be susceptible to developing lactic acidosis due 
to reduced renal dysfunction resulting in 
impaired clearance of biguanides [20, 34]. The 
incidence of lactic acidosis due to buformin is 
not known. There are case reports of buformin-
induced lactic acidosis, as buformin is approved 
for use in many European and Asian countries 
[35]. However, despite this potential side effect, 
we believe that buformin could be safely 
applied for use in cancer patients with appro-
priate patient selection (i.e normal renal 
function). 
We hypothesize that the efficacy of biguanides 
will be best appreciated when used in combina-
tion with traditional cytotoxic therapies. The 
administration of metformin together with 
paclitaxel, carboplatin or doxorubicin has been 
shown to block tumor growth and prolong 
relapse rate in a variety of mouse xenografts 
[36]. The combination of phenformin and 
PLX4720 (a BRAF inhibitor) synergistically 
induced tumor regression in nude mice bearing 
melanoma xenografts and in a genetically engi-
neered BRAFV600E/PTEN null-driven mouse 
model of melanoma [37]. Our previous study 
found that metformin potentiated the effects of 
paclitaxel in endometrial cancer cells through 
modulation of the mTOR pathway [25]. In this 
study, we treated both ECC-1 and Ishikawa cells 
with varying doses of paclitaxel alone, in combi-
nation with 0.1 or 1 μM buformin. The addition 
of buformin at 0.1 and 1 μM to paclitaxel led to 
a greater inhibition of cell proliferation than 
that of paclitaxel alone in both cell lines (CI<1). 
It is not surprising that low doses of buformin 
sensitizes the cytotoxicity of paclitaxel in endo-
metrial cancer cell lines given that it shares the 
same targeting pathways as metformin. 
Clinically, the combination of buformin and 
paclitaxel would allow for the use of lower 
doses of paclitaxel and a resultant decrease in 
toxicity associated with paclitaxel, without 
impacting the efficacy of treatment. 
In summary, we find that buformin has anti-pro-
liferative and anti-metastatic effects in endo-
metrial cancer cells. Although the risk/benefit 
ratio clearly favors metformin over buformin for 
the treatment of diabetes, this may not hold 
true for the treatment of cancer, especially if 
buformin is found to have greater anti-tumori-
genic activity than metformin. Given our prom-
ising results, future studies conducted in our 
laboratory will focus on evaluating the effects 
of buformin versus metformin on tumor growth 
in genetically engineered models of endometri-
al cancer.
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